Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2249-2259

  Ekman, Evan F ^a   Gimbel, Joseph S ^b   Bello, Alfonso E ^c   Smith, Michael D ^d   Keller, David S ^d   Annis, Karen M ^d   Brown, Mark T ^d   West, Christine R ^d   Verburg, Kenneth M ^d  

^a Appalachian Regional Orthopaedic and Sports Medicine   (United States)

^b Phoenix Orthopedic Surg   (United States)

^c ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^d PFIZER INC   (United States)

Author keywords

Efficacy safety; Naproxen; Osteoarthritis; Tanezumab

Indexed keywords

CREATINE KINASE; NAPROXEN; PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLODYNIA; ANALGESIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BURNING SENSATION; CANADA; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; FALLING; FEMALE; GENERAL CONDITION DETERIORATION; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPERESTHESIA; HYPESTHESIA; JOINT SWELLING; KNEE OSTEOARTHRITIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NEURALGIA; PAIN ASSESSMENT; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIBRATION DISEASE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; JOINT CHARACTERISTICS AND FUNCTIONS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATIENT SAFETY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAPROXEN; ONTARIO; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATIENT SAFETY; RANGE OF MOTION, ARTICULAR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84923227262     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131294     Document Type: Article

References (29)

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81:646-56.
2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43:1905-15.
3. American Academy of Orthopaedic Surgeons. The treatment of osteoarthritis of the knee (non-arthroplasty). [Internet. Accessed September 16.] Available from: www.aaos.org/research/guide-lines/TreatmentofOsteoarthritisoftheKneeGuideline.pdf.
4. Jordan KM, Arden NK, Doherty M, Bannwarth B., Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62:1145-55.
5. Zhang W, Moskowitz RW, Nuki G, Abramson S., Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16:137-62.
6. Pincus T, Swearingen C, Cummins P., Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27:1020-7.
7. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1, 799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43:378-85.
8. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 2008; 22:349-59.
9. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008; 17:1326-35.
10. Hefti FF, Rosenthal A, Walicke P.A., Wyatt S., Vergara G, Shelton DL, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006; 27:85-91.
11. Brown MT, Murphy FT, Radin D.M., Davignon I., Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012; 13:790-8.
12. Brown MT, Murphy FT, Radin D.M., Davignon I., Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase 3 trial. Arthritis Rheum 2013; 65:1795-803.
13. Lane NE, Schnitzer TJ, Birbara C.A., Mokhtarani M., Shelton DL, Smith MD, et al. Tanezumab for treatment of knee osteoarthritis pain. N Engl J Med 2010; 363:1521-31.
14. Nagashima H, Suzuki M, Araki S., Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011; 19:1405-12.
15. Schnitzer TJ, Lane NE, Birbara C, Smith M.D., Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011; 19:639-46.
16. Spierings EL, Fidelholtz J, Wolfram G., Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013; 154:1603-12.
17. Altman R, Asch E, Bloch D., Bole G, Borenstein D, Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039-49.
18. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494-502.
19. Bellamy N, Buchanan WW, Goldsmith C.H., Campbell J., Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833-40.
20. Stengaard-Pedersen K, Ekesbo R, Karvonen A.L., Lyster M. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology 2004; 43:592-5.
21. Apfel SC, Schwartz S, Adornato B.T., Freeman R., Biton V, Rendell M, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284:2215-21.
22. Dyck PJ, Litchy WJ, Lehman K.A., Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45:1115-21.
23. Pfizer Inc. Tanezumab Arthritis Advisory Committee briefing document. [Internet. Accessed August 7, 2014.] Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295205.pdf.
24. Hochberg MC, Abramson S B, Hungerford DS, McCarthy E, Vignon E.P., Smith MD, et al. Adjudication of reported serious adverse joint events in the Tanezumab Clinical Development Program [abstract]. Arthritis Rheum 2012; 64 Suppl: S113.
25. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologies Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). [Internet. Accessed August 7, 2014.] Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071577.pdf.
26. Moskowitz RW, Sunshine A, Brugger A., Lefkowith JB, Zhao WW, Geis GS. American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies. Am J Ther 2003; 10:12-20.
27. Zorbas M, Hurst S, Shelton D., Evans M, Finco D, Butt M. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol 2011; 59:334-42.
28. FDA Center for Drug Evaluation and Research. Background materials. Meeting of the Arthritis Advisory Committee (AAC). [Internet. Accessed August 7, 2014]. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295202.pdf.
29. FDA Center for Drug Evaluation and Research (CDER). Background materials addendum. [Internet. Accessed August 7, 2014.] Available from: www.fda.gov/downloads/AdvisoryCommitlees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisory Committee/UCM295203.pdf.